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Graft-versus-host disease (GVHD) continues to be a leading cause of morbidity and mortality after allogeneic
hematopoietic stem cell transplantation. Recent insights into intestinal homeostasis and uncovering of new
pathways and targets have greatly reconciled our understanding of GVHD pathophysiology and will reshape
contemporary GVHD prophylaxis and treatment. Gastrointestinal (GI) GVHD is the major cause of mortality.
Emerging data indicate that intestinal stem cells (ISCs) and their niche Paneth cells are targeted, resulting in
dysregulation of the intestinal homeostasis and microbial ecology. The microbiota and their metabolites shape
the immune system and intestinal homeostasis, and they may alter host susceptibility to GVHD. Protection of
the ISC niche system and modiﬁcation of the intestinal microbiota and metabolome to restore intestinal
homeostasis may, thus, represent a novel approach to modulate GVHD and infection. Damage to the intestine
plays a central role in amplifying systemic GVHD by propagating a proinﬂammatory cytokine milieu. Mo-
lecular targeting to inhibit kinase signaling may be a promising approach to treat GVHD, ideally via targeting
the redundant effect of multiple cytokines on immune cells and enterocytes. In this review, we discuss insights
on the biology of GI GVHD, interaction of microﬂora and metabolome with the hosts, identiﬁcation of potential
new target organs, and identiﬁcation and targeting of novel T cellesignaling pathways. Better understanding
of GVHD biology will, thus, pave a way to develop novel treatment strategies with great clinical beneﬁts.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION disease relapse, and long-term adverse effects. Data suggest
Acute graft-versus-host disease (GVHD) is an immuno-
logically mediated process, involving donor T cell responses
to host alloantigens and the dysregulation of inﬂammatory
cytokine cascade after allogeneic hematopoietic stem cell
transplantation (allo-SCT). Studies on GVHD pathophysi-
ology have been primarily focusing on mechanisms of T cell
activation in the induction phase of GVHD. Recent studies on
the fundamental mechanisms of the target injury highlight
complex interactions between different effector cell type and
target cells in peripheral tissue. Particularly, gastrointestinal
(GI) tract damage and subsequent alteration of the intestinal
homeostasis play important roles in amplifying GVHD [1].
Emerging data suggest that alterations in the intestinal
microbiota and metabolome also play crucial roles in
modulating the severity of acute GVHD.
Current GVHD prophylaxis and treatment are only
partially effective, with an increased risk for infections,dgments on page 15.
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ty for Blood and Marrow Transplantation.that use of T celledirected immunosuppressants potentially
inhibits tolerance induction, at least in part by suppressing
regulatory T cell (Treg) homeostasis [2]. Cytokines and
chemokines are the major players in GVHD and blockade of
TNF-a, IL-6, and C-C chemokine receptor type 5 (CCR5) has
been tested based on data from mouse models [3-7]. Recent
progress in our understanding of signaling pathway and
molecular targeting enables us to target the redundant effect
of multiple cytokines. Thus, better understanding and amore
targeted approach of signaling pathways in T cells with a
newer class of immunomodulatory approaches could lead to
more effective control of GVHD. In this review, we discuss
newer experimental insights on the biology of GI-GVHD and
the interaction of intestinal microbiota and metabolome
with the host and novel strategies for T cellesignaling
manipulation in the regulation of GVHD.EMERGING CONCEPTS ON TISSUE INJURY IN GVHD
Disruption of the Intestinal Homeostasis and Microbial
Ecology in GI GVHD
Intestinal GVHD is characterized by severe villous atrophy
and crypt degeneration, but the crypt cell degeneration has
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[8-10]. Intestinal stem cells (ISCs) and their niche Paneth
cells reside within the crypts and play a pivotal role in both
physiologic tissue renewal and regeneration of the injured
epithelium. We and others have tested the hypothesis that
ISCs and their niche could be primary targets in GVHD in
mice [11-13]. Irradiation induces apoptosis of ISCs within
24 hours while sparing Paneth cells, but ISCs rapidly recover
and restore the normal architecture of the small intestine in
the absence of GVHD [12,14]. However, once GVHD develops,
both ISCs and Paneth cells do not recover, indicating that
the ISC-niche system is the target in intestinal GVHD
(Figure 1) [11-13].
Secretory cells, such as Paneth cells and goblet cells, play a
critical role in maintaining intestinal microbial ecology and
protecting hosts from pathogens. Paneth cells shape the
microbial composition by secreting a range of antimicrobial
peptides, such as a-defensins [15]. In GVHD, Paneth cell loss
results in a reduced secretion of a-defensins, leading to
intestinal dysbiosis [13,16-19]. Goblet cells shield the
epithelium from luminal bacteria by secreting mucin [20].
Goblet cell injury in GVHD permits translocation and
dissemination of dominant luminal pathogens, which
further accelerates GVHD and creates a vicious cycle of GVHD
and infections [21,22]. These mechanisms explain why GI
GVHD is often prolonged and refractory to treatment and
represents a risk factor for septicemia. These ﬁndings have
been conﬁrmed in human studies; loss of Paneth cells and
dysbiosis are hallmarks of GI GVHD and associated with
increased nonrelapse mortality [17,23-26]. The effects of
innate cells, such as neutrophils, monocytes, and innate
lymphoid cells, in target injury are also now becoming
known [11,27,28].Figure 1. Homeostasis of self-renewing small intestinal epithelium results from ISCs
Paneth cells. IL-22 produced from innate lymphoid cells (ILCs) upon stimulation of
renewal and differentiation of ISCs. Paneth cells maintain intestinal microbial ecol
shield the epithelium from luminal bacteria by secreting mucin. Intestinal homeosta
intestinal microbiota and its metabolites, such as butyrate. After allo-SCT, donor T cells
system. Paneth cell loss results in a reduced secretion of AMPs, leading to intestinal
luminal pathogens and pathogen-associated molecular patterns, which further acc
pathways are required for responses to multiple cytokines and, thus, represent potenThe intestinal microbiota has been given a putative role in
the pathogenesis of GVHD since the pioneering studies in the
early 1970s [29,30]. Although the focus so far has been on
bacteria and their metabolites, several clinical observations
have also suggested a role for Candida in the pathogenesis
of GVHD; Candida colonization in the gut is a risk of acute
GVHD (aGVHD) and antifungal prophylaxis with ﬂuconazole
reduced aGVHD [31,32]. However, a mechanistic link be-
tween fungal infection and GVHD has never been demon-
strated. A component of the Candida cell wall, a-mannan, is
recognized by the C-type lectin receptor Dectin-2 and stim-
ulates macrophages to produce cytokines, such as IL-6 and
IL-23, which drive a Th17-skewed response [33]. A lung-
speciﬁc chemokine/cytokine environment in GVHD leads to
accumulation of Th17 cells in the lung [33,34]. a-Mannan or
heat-killed Candida albicans exacerbate systemic aGVHD,
particularly in the lung [33]. Thus, not only bacteria but
also fungi residing on the mucosal surface play an important
role in GVHD. Th1 and Th17 responses may differentially
contribute to tissue-speciﬁc aGVHD. However, studies using
an IL-17 fate-mapping reporter highlight the complex
plasticity and heterogeneity in cytokine expression in
effector T cell subsets involved in the development of GVHD
[33-36], which will need further elucidation to guide rational
development of preventive and therapeutic interventions.
Protection of the ISC Niche System as a Novel Approach to
Restore Intestinal Homeostasis and Control GVHD
Attention has now begun to focus on protection of the ISC
niche system to regulate GVHD. ISCs express IL-22 receptors
[11]. Recipient IL-22 deﬁciency increases crypt apoptosis,
loss of ISCs, and GVHDmortality [11]. Administration of IL-22
may be a promising strategy to protect ISCs [37]. Wnt agonist, which locate at the base of the crypts and interspersed between their niche
IL-23 from antigen-presenting cells (APCs) and R-spondins play a role in self-
ogy by secreting antimicrobial peptides (AMPs) into the lumen. Goblet cells
sis depends on proper interaction between the mucosal immune system and
and inﬂammatory cytokines, such as TNF, IL-6, and IL-1, damage the ISC-niche
dysbiosis. Tissue injury permits translocation and dissemination of dominant
elerates GVHD by propagating a proinﬂammatory cytokine milieu. JAK-STAT
tial new targets in GVHD.
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ISCs [39]. Brief administration of R-Spo1 interrupts acceler-
ation of GVHD by protecting ISCs from conditioning, facili-
tating wound healing, and inhibiting the inﬂammatory
cytokine milieu in mice [12]. We also showed that R-Spo1
stimulates ISCs to differentiate into secretory cells. R-Spo1
thus inhibits the GVHD-associated dysbiosis and trans-
location of the luminal bacteria by promoting Paneth cell
secretion of a-defensins and preserving the GI mucus layer.
Interestingly, the survival beneﬁt mediated by R-Spo1 was in
part abrogated when mice were treated with oral broad-
spectrum antibiotics, suggesting a link between GVHD and
intestinal commensals. Intestinal homeostasis depends on
proper interaction between themucosal immune system and
intestinal microbiota and its metabolites. Identiﬁcation of
the speciﬁc bacteria and associated products that affect
transplantation outcome is now an active area of investiga-
tion [40]. Such a novel pharmacological approach to protect
the ISC niche system and modulating the intestinal envi-
ronment may shape host immune system toward less GVHD
while preserving graft-versus-leukemia (GVL) activity [41].
Previously Unrecognized Target Organs of Acute GVHD
Although aGVHD typically targets the skin, GI tract, and
liver, recent experimental studies suggest previously unrec-
ognized organs as potential targets of aGVHD. It has been
shown that GVHD is a risk for neurological complications and
infertility [42,43]. Recent studies in mice and primates
demonstrated signiﬁcant donor T cell inﬁltration of the
central nervous system with damage of neurons and
neuroglia during aGVHD, leading to behavioral abnormalities
[44,45]. We also found donor T cell inﬁltration in the ovary
with apoptosis of ovarian cells, leading to impairment of
ovary functions and infertility. Pharmacological GVHD pro-
phylaxis preserved fertility after allo-SCT with a minimally
toxic conditioning regimen [46]. These results may have
important clinical implications in young female transplant
recipients with nonmalignant diseases, where minimally
toxic conditioning regimens are used. Such increasingly
appreciated manifestations of GVHD in animals deserve
further clinical scrutiny.
MICROBIAL METABOLITES AND HISTONE ACETHYLATION
OF GI EPITHELIUM IN GVHD
Histone Deacetylate Inhibitors and GVHD
Histone acetylation regulates transcriptional activation.
Lysine residues at the amino-terminus of histone H3 and H4
tails are acetylated by histone acetyltransferase enzymes or
deacetylated by histone deacetylase (HDAC), leading to
modiﬁcations in DNA accessibility. HDAC inhibition results in
the accumulation of hyperacetylated histones, thereby
altering the patterns of gene expression [47]. Beside their
role in cancer, HDAC inhibitors (HDACi), at lower and non-
cytotoxic concentrations, possess anti-inﬂammatory and
immunoregulatory effects [48]. Animal studies of allo-SCT
have shown that HDACi suppress proinﬂammatory
cytokine production, reduce GVHD, and preserve GVL
by modulating indoleamine-2,3-dioxygenaseedependent
innate immune and allo-stimulating functions of antigen-
presenting cells in a STAT-3-dependent manner [47,49].
HDACi also enhance natural Treg functions [47,50]. A recent
single-arm, phase I/II, ﬁrst-in-human clinical trial with
HDACi vorinostat in adult patients with high-risk hemato-
logical malignancies after HLA-matched related donor SCT
showed potential for preventing severe GVHD [51]. Histoneacetylation regulates the epigenetic landscape of GVHD
target tissues as well [52]. However, the role of histone
acetylation and its dependent epigenetic regulation in GVHD
target tissues, speciﬁcally, the GI tract, and the impact on
overall severity of GVHD, remains largely unknown.
Intestinal Metabolome in GVHD
The microbiota are known to perform key metabolic
functions; they metabolize not only material directly inges-
ted by the host but also produce byproducts of its own
metabolism [53]. The intestinal metabolome thus consists of
products from discrete host metabolism, microbial meta-
bolism, and mammalian-microbial cometabolism [54]. The
impact of microbiota-derived metabolites is being increas-
ingly appreciated, speciﬁcally in intestinal homeostasis [55].
Recent studies show that colonocytes from germ-free mice
are in an energy-deprived state, which in turn result in
autophagy [56].
In addition to the effects of microbial metabolites on
nonimmune cells, the impact of the metabolome on immune
cells is now becoming increasingly understood. Recent
studies have shown that 17 rationally selected strains of
Clostridia, known to produce the short chain fatty acid (SCFA)
butyrate, directly result in the increased presence of Tregs
in the gut [57]. Tregs play a critical role in maintaining GI
homeostasis by modulating inﬂammatory responses via the
release of the anti-inﬂammatory molecule IL-10, which also
directly impact macrophages [58]. Diet plays a role in regu-
lating rapid changes in the taxonomic composition of the gut
microbiota and an appropriate diet conducive to homeostatic
microbiota may be an important factor when treating
comorbidities, as the associated metabolome is corre-
spondingly altered [59]. Butyrate, a critical SCFA, is an HDACi.
Together, these data suggest the microbial metabolome,
more speciﬁcally intestinal butyrate, might impact GVHD,
although this hypothesis has heretofore not been formally
tested.
Many recent studies have made strides in identifying the
taxonomic composition and activity of the host microbiome.
Although it is increasingly evident that alterations in the
microbiome correlate with many disease states, including
GVHD [13,17,19], the mechanism through which these alter-
ations confer their effects is poorly understood. The most
studied microbial metabolites SCFAs are produced by
microbial fermentation of complex polysaccharides in the
gut and are subsequently absorbed by the intestinal epithe-
lium [60]. Butyrate is utilized as a major energy source for
intestinal epithelial cells [60]. Thus, microbial metabolites
may play an important role in maintaining the health of the
physical barrier of the gut epithelium as well as protecting
the host from the inﬂuences of pathogen-associated molec-
ular patterns and damage-associated molecular patterns.
SCFAs may have a particularly important role in the protec-
tion of the host from GVHD. Observations from our lab,
exploring the generation of SCFAs and the impact on intes-
tinal tissues and GVHD, will be discussed [61].
Brieﬂy, inﬂammation after allo-SCT reduced histone
acetylation in the IECs of the hosts in association with
reduced butyrate within the IECs. We explored whether the
alterations in acetylation and butyrate levels within the IECs
after allo-SCT correlated with luminal SCFA levels that are
exclusively made by intestinal microﬂora after allo-SCT. Sur-
prisingly, the concentrations of the SCFAs were not signiﬁ-
cantly different in serum or tissues, such as the spleen and
liver, of allogeneic animals compared with syngeneic animals
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tistically signiﬁcant difference was, unexpectedly, observed
in just 1 SCFA, butyrate, which was signiﬁcantly decreased
only in the intestinal tissue after allo-SCT. The reduced buty-
rate in CD326þ IECs after allo-SCT contributed to decreased
histone acetylation, because this was restored upon local
administration of exogenous butyrate. Furthermore, increasing
local delivery of butyrate resulted in improved IEC junctional
integrity, increased antiapoptotic proteins, decreased GVHD,
and improved survival. In addition, alteration of the indige-
nous microbiota with 17 rationally selected strains of high
butyrateeproducing Clostridia [57] also decreased GVHD and
increased survival after allo-SCT. These data demonstrate a
heretofore unrecognized role of microbial metabolites and
suggest that local and speciﬁc alterations of microbial me-
tabolites have direct salutary effects on GVHD target tissues
and can mitigate its severity.
KINASE INHIBITION FOR GVHD TREATMENT
Identiﬁcation and Targeting of Novel T Cell signaling
Pathways
Besides the role of kinases in cancer, abnormal activation
of certain kinases is a hallmark of many inﬂammatory
diseases. Examples are abnormal PI3 kinase delta activation
in activated PI3 kinase delta syndrome, increased Janus
kinase (JAK) activity in rheumatoid arthritis and ulcerative
colitis, or abnormal spleen tyrosine kinase (SYK) activity
in immune thrombocytopenic purpura and rheumatoid
arthritis. Consistent with a role of many kinases in different
immune cells during autoimmunity, a number of kinases
have been reported to be targets in GVHD. Analyses of the
role of different kinases in GVHD were done via the use of
kinase inhibitors, mostly in a prophylactic setting in different
murine models of GVHD or by the use of gene-targeted
mice lacking the respective kinase. Kinases identiﬁed to be
potential targets in GVHD by these approaches include rho-
associated coiled coil kinase [62], protein kinase C (PKC)a
[63], PKCq [63,64], SYK [65-68], JAK 1/2 [69-72], JAK3 [73],
cyclin dependent kinases [74], mitogen-activated protein
kinase kinase [75], and Bruton’s tyrosine kinase [76]. Strong
evidence for a preclinical and clinical efﬁcacy exist for SYK
and JAK1/2 inhibition in GVHD, based on multiple publica-
tions of independent groups [65-72]. SYK is an intracellular
nonreceptor tyrosine kinase involved in multiple signaling
events of immune cells and has shown activity in aGVHD [65]
and chronic GVHD (cGVHD) [66,67]. Intact SYK is required for
extracellular signal-regulated kinases (ERK) activation and
nuclear factor of activated T cells (NFAT) transcriptional
activation [77], and recognition of certain peptides affords
SYK for TCR signaling [78]. In our previous work, we showed
that SYK is required for the development of aGVHD by using
a pharmacological inhibitor [65], which was later extended
by other groups to cGVHD [66-68]. SYK inhibition with fos-
tamatinib reduced in vivo expansion of donor T cells and
dendritic cell (DC) migration in mice developing aGVHD
without blocking antivirus and GVL responses [65]. In
cGVHD, fostamatinib treatment normalized germinal center
formation and decreased activated CD80/86þ DCs [67]. The
effects of SYK inhibition could be connected to the hemato-
poietic system, as bone marrowespeciﬁc SYK deletion
reduced established cGVHD [67]. Beside their investigation
in mice, Flynn et al. also showed that SYK inhibition was
effective at inducing apoptosis in human B cells derived from
individuals with cGVHD [67].JAK Inhibition for GVHD Treatment
A group of kinases that were recently shown to be
potential targets in GVHD are JAK 1, 2, and 3 [69-72]. When
these kinases are activated, signal proteins of the STAT
family are phosphorylated, which act as transcription
factors for target genes that serve proinﬂammatory roles.
Among other functions, JAK1 and 2 are required for re-
sponses to multiple cytokines [79]. Signaling through the
common g-chain, a constituent of the receptor complexes
for 6 different interleukins, including IL-2, IL-4, IL-7, IL-9,
IL-15, and IL-21 [80], is mediated via JAK1. Signaling
through the common g-chain was recently identiﬁed as a
therapeutic target in aGVHD and cGVHD [72]. Blockade of
multiple cytokines by inhibition of the downstream
signaling could avoid the redundant effect of most cyto-
kines. This could help overcome the unsatisfactory results
reported when a single cytokine is inhibited. Another event
where JAK1/2 inhibition may interfere with GVHD is DC
activation, which was shown to depend on JAK1/2 activa-
tion [81]. Additionally, JAK1/2 signaling plays a central role
in the activation of neutrophils [82], which we and others
connected to the pathogenesis of aGVHD [83-85]. Based on
the preclinical evidence, the efﬁcacy of the JAK1/2 inhibitor
ruxolitinib was recently assessed in a retrospective survey
[86]. Ninety-ﬁve mostly heavily pretreated patients who
had received ruxolitinib as salvage therapy for steroid
refractory (SR) aGVHD or cGVHD were reported [86]. The
6-month-survival of the patients treated with ruxolitinib
was 79% (95% conﬁdence interval, 67.3% to 90.7%) and 97.4%
(95% conﬁdence interval, 92.3% to 100) for SR aGVHD and SR
cGVHD, respectively. Trials of SR GVHD are heterogeneous,
making direct comparison of different agents difﬁcult [87].
The weighted average 6-month survival estimate across 25
retrospective or phase II trials on SR aGVHD was 49% [87].
The largest study analyzed the effect of antithymocyte
globulin as a second-line treatment and included 79
patients [88]. The 6-month survival estimate for this study
was 44% [88]. The use of ruxolitinib for SR GVHD was con-
nected to an overall response rate of 81.5% (44 of 54) in SR
aGVHD, including 25 complete remissions (46.3%), whereas
for SR cGVHD, the overall response rate was 85.4% (35 of 41)
[86]. When only patients responding to ruxolitinib were
analyzed, the rate of GVHD relapse was 6.8% (3 of 44) and
5.7% (2 of 35) for SR aGVHD and SR cGVHD, respectively
[86]. Major side effects during ruxolitinib treatment
included cytopenia and cytomegalovirus reactivation in
both SR aGVHD and SR cGVHD patients, which were, how-
ever, comparable to other reported immunosuppressive
approaches, including steroids, inﬂiximab, alemtuzumab,
mycophenolate mofetil, or cyclosporine [89-91].
A major concern of pharmacological immune modulation
via kinase inhibition is the loss of GVL activity. Reduced GVL
effects were observed, for example, when PKCa and PKCq
proteins were inhibited [62]. Relapse of the underlying ma-
lignancy in ruxolitinib-treated patients was low, as only 9.3%
and 2.4% of the patients with aGVHD or cGVHD, respectively,
had disease recurrence [86]. Major limitations for a broad
clinical application of kinase inhibitors in allo-SCT are the
moderate speciﬁcity of many compounds as off-target inhi-
bition can lead to considerable side effects. Additionally, GVL
and antimicrobial effects need to be preserved, as purely
immunosuppressive effects would not lead to an advantage
over already established immunosuppressive drugs that are
routinely used in clinical practice.
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